Azilect News and Research

RSS
Study finds link between extended use MAO-B inhibitors and slow clinical decline in PD patients

Study finds link between extended use MAO-B inhibitors and slow clinical decline in PD patients

Teva to present abstracts on AZILECT at MDS meeting

Teva to present abstracts on AZILECT at MDS meeting

Teva initiates enrollment in AZILECT Phase IV clinical study for PD-MCI

Teva initiates enrollment in AZILECT Phase IV clinical study for PD-MCI

Teva third quarter 2012 net revenues increase 14% to $5.0 billion

Teva third quarter 2012 net revenues increase 14% to $5.0 billion

Teva first quarter net revenues increase 25% to $5.1 billion

Teva first quarter net revenues increase 25% to $5.1 billion

Teva fourth quarter net revenues increase 28% to $5.7 billion

Teva fourth quarter net revenues increase 28% to $5.7 billion

Avraham raises $3M to advance ladostigil Phase II Alzheimer's trial

Avraham raises $3M to advance ladostigil Phase II Alzheimer's trial

Teva third quarter net sales increase 2% to $4.34 billion

Teva third quarter net sales increase 2% to $4.34 billion

Teva second quarter net sales increase 11% to $4.2 billion

Teva second quarter net sales increase 11% to $4.2 billion

Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Teva fourth quarter net sales increase 16% to record $4.4 billion

Teva fourth quarter net sales increase 16% to record $4.4 billion

Lundbeck A/S third quarter revenue increases 7% to DKK 3,619 million

Lundbeck A/S third quarter revenue increases 7% to DKK 3,619 million

Teva third quarter net sales increase 20% to $4.3 billion

Teva third quarter net sales increase 20% to $4.3 billion

Watson seeks FDA approval to market rasagiline mesylate tablets

Watson seeks FDA approval to market rasagiline mesylate tablets

TEMPO study recommends early administration of Azilect in PD patients

TEMPO study recommends early administration of Azilect in PD patients

Teva second-quarter net sales increase 12% to $3.8 billion

Teva second-quarter net sales increase 12% to $3.8 billion

Study confirms Azilect as a selective MAO-B inhibitor

Study confirms Azilect as a selective MAO-B inhibitor

Teva reports 31% increase in non-GAAP net income for first-quarter 2010

Teva reports 31% increase in non-GAAP net income for first-quarter 2010

Teva Pharmaceutical Industries presents ADAGIO study results at AAN Annual Meeting

Teva Pharmaceutical Industries presents ADAGIO study results at AAN Annual Meeting

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010